MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a clinical-stage company pioneering intelligent decongestion management therapy for acute decompensated heart failure (ADHF), today ...
BOSTON, MA—The Reprieve decongestion management system (Reprieve Cardiovascular) appears to safely manage patients hospitalized with acute heart failure (HF) and significant volume overload, according ...
MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart ...
German-American medical device firm, Reprieve Cardiovascular, is eyeing up a pivotal trial with its cardiovascular drainage device after reporting success from a first-in-human study. Results from the ...
Reprieve Cardiovascular recently emerged from stealth mode after raising $42 million in series A financing. The Milford, MA-based company is developing a system intended to personalize decongestion ...
Hosted on MSN
Reprieve secures $61m for ADHF system trial
Reprieve Cardiovascular has closed an oversubscribed $61m Series B financing round, which was spearheaded by Deerfield Management. The funds aim to accelerate the global FASTR II pivotal trial of the ...
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results